Real-world Retrospective Study Of Second-line Treatment With Ratitrexed Regimen In Advanced Colorectal Cancer

Objective:The clinical data of patients with advanced colorectal cancer who received second-line treatment with raltitrexed were collected retrospectively.To observe the efficacy and adverse reactions of the second-line regimen containing raltitrexed in the treatment of advanced colorectal cancer under clinical real-world conditions,and analyze important predictive factors related to the efficacyMethods:This study retrospectively collected 150 patients with advanced colorectal cancer who were pathologically diagnosed in our hospital.Among them,the basic information and clinical data of 89 patients were complete and evaluable.After 89 patients progressed using the standard first-line chemotherapy regimen,the second-line chemotherapy regimen containing raltitrexed was used.The basic information,clinical characteristics,hematological test results,imaging test results,drug efficacy and adverse reactions of the selected cases were collected.The main endpoint is progression-free survival(PFS).Use statistical software SPSS 26.0 to perform statistical analysis on clinical data,use Kaplan-Meier survival analysis method to perform Log-rank single factor test and draw survival curve,use Cox regression model to perform multivariate analysis on single factor meaningful indicators,and find the second line of influence The independent predictor of treatment,P<0.05 indicates that there is a statistical difference.Results:A total of 89 patients with advanced colorectal cancer with fully evaluable data were included in this study.After treatment with the second-line regimen containing raltitrexed,the first efficacy evaluation was based on the RECIST 1.1 standard.Log-rank univariate analysis showed that the use time of fluorouracil,the number of distant metastatic organs,CEA and CA199 were related to the second-line treatment of advanced colorectal cancer with raltitrexed regimen.The results of multivariate COX regression analysis showed that the use time of first-line fluorouracil affected the use of ray The second-line regimen of tetroxed is an independent predictor of PFS for advanced colorectal cancer.The use time>6 months is an adverse prognostic factor that affects PFS in patients with advanced colorectal cancer.The results of short-term efficacy evaluation:Among them,0 cases were CR,20 cases were PR,48 cases were SD,21 cases were PD,ORR(CR+PR)was 22.47%,and DCR(CR+PR+SD)was 76.4%.Adverse reactions:leukopenia(34.8%)(mainly neutropenia 30.3%),nausea and vomiting(28.1%),diarrhea(20.2%),rash(19.1%),elevated transaminase(19.1%),peripheral nerves Toxicity(13.5%),epistaxis(11.2%),thrombocytopenia(5.62%),hypertension(5.6%),etc.Mainly Ⅰ-Ⅱ degree adverse reactions,only 2 cases(2.25%)had Ⅲ-Ⅳ degree leukopenia and neutropenia.Conclusion:1.The second-line treatment of advanced colorectal cancer with raltitrexed has a definite effect,and the side effects can be tolerated.The mPFS reached 5.8 months,the ORR was 22.47%,and the DCR was 76.4%.2.The use time of first-line 5-FU>6 months is a poor prognostic factor that affects PFS in patients with advanced colorectal cancer in the second-line treatment with raltitrexed...